Фулвестрант Ромфарм

Фулвестрант Ромфарм is an intramuscular estrogen receptor antagonist used in hormone receptor-positive breast cancer therapy. This prescription medication helps block estrogen effects to slow tumor growth. Fulvestrant Rompharm is administered by healthcare professionals for targeted treatment. Always consult a doctor before use.

Fulvestrant Rompharm is prescribed for treating hormone receptor-positive metastatic breast cancer in postmenopausal women. It is used when cancer has progressed after hormone therapy. The medication works by binding to estrogen receptors, preventing estrogen from stimulating cancer cell growth. Fulvestrant is typically used after other hormonal treatments have been tried.

Fulvestrant Rompharm may help reduce cancer progression by blocking estrogen receptors in breast tissue. Patients may experience improved symptoms related to their condition over time. Common effects include injection site reactions and mild gastrointestinal discomfort. Individual responses vary based on treatment duration and health status.

Fulvestrant Rompharm should only be administered by trained healthcare providers. Patients with bleeding disorders or low platelet counts require careful monitoring. Inform your doctor about all medications and medical conditions before starting treatment. Regular follow-ups are essential to assess treatment progress and manage side effects.

Fulvestrant Rompharm may interact with blood thinners like warfarin, requiring dose adjustments. Combining with other hormonal therapies could affect efficacy or increase side effects. CYP3A4 inhibitors may alter fulvestrant levels in the body. Always disclose all prescription and over-the-counter medications to your healthcare provider.